News Sentiment

CRIS sentiment intelligence

Curis Inc news scored across direct company coverage, industry context, sector read-through, source quality, and freshness.

Chart Weekly report Factors RSS feed
Weighted score 50 Balanced news tone 63 relevant articles
Exchange NASDAQ United States
Sector Healthcare Market context
Industry Biotechnology Read-through group
Latest close 4.63 Week of 17 Jul 2026
Weighted tone 50/100

Balanced news tone

Market reaction Price moving ahead of tone

Price is moving more forcefully than the current news tone suggests.

Primary event Market update

78/100 classification confidence.

Company focus 54

directly relevant articles

Source quality 0

high-authority source matches

Trend context Trend inactive

-6.7% over one week, -45.0% over four weeks, trend inactive, and below fair value.

Latest direct headline Positive

Curis stock jumps 11% on positive emavusertib trial data By Investing.com

Market Reaction

Price moving ahead of tone

57/100 confidence

Price is moving more forcefully than the current news tone suggests.

Primary event Market update 78/100 classification
One-week reaction -6.7% Price reacting lower
Trend fit Trend inactive -45.0% over four weeks
Fair value -95.3% Below fair value
Value support

Sentiment Mix

Positive, neutral, negative

Weighted by relevance
Positive 7
Neutral 50
Negative 6

Relevance

Why the article matched

Direct first
Direct company coverage 54
Industry context 9
Sector context 0

Sources

Coverage mix

Publishers
Stock Titan 14
TradingView 13
Market source 8
PR Newswire 7
simplywall.st 4
Simply Wall Street 2
GuruFocus 2
Investing.com Nigeria 1

Event Lens

What the news is about

Classified themes
Market update 32
Earnings 22
Guidance 3
Analyst action 3
Balance sheet 2
Capital return 1

Sentiment Trail

Score over time

50 baseline
Above 50 Neutral zone Below 50

News Tape

Relevant headlines

Showing 31-60 of 63
Moomoo Direct company coverage

Curis Consents 6 Patients in Phase 2 Trial of Emavusertib in Chronic Lymphocytic Leukemia

Curis announced that it has consented six patients in its Phase 2 trial of emavusertib for chronic lymphocytic leukemia (CLL). This development marks progress in evaluating the drug's potential for CLL treatment. Further details regarding the trial's progress and patient enrollme

Tone
Positive 68/100
Event
Market update
Published
06 Jul 2026 14:09
Source
Moomoo
Intellectia AI Direct company coverage

Curis Achieves Key Milestone in TakeAim CLL Study

Curis has enrolled the first six patients in its TakeAim CLL study, with plans to dose five by July 2026, and expects to release initial clinical data in December 2026. The study aims to combine emavusertib with zanubrutinib to target chronic lymphocytic leukemia. Despite this pr

Tone
Negative 40/100
Event
Guidance
Published
06 Jul 2026 14:09
Source
Intellectia AI
PR Newswire Direct company coverage

Curis Consents First Six Patients in TakeAim CLL Study

Curis, Inc. has enrolled the first six patients in its TakeAim CLL study, with eleven clinical sites already opened. The company expects to dose an initial five CLL patients by the end of July 2026 and release initial data in December 2026. This study combines emavusertib with a

Tone
Positive 66/100
Event
Guidance
Published
06 Jul 2026 13:09
Source
PR Newswire
Ad-hoc-news.de Direct company coverage

Curis Inc outlines oncology pipeline as investors watch funding and trial progress

Curis Inc, a clinical-stage biotech company, is advancing its targeted cancer pipeline, balancing funding needs with development timelines. The company focuses on precision medicines for oncology, developing small molecules to modulate key signaling pathways. Its financial stabil

Tone
Neutral 50/100
Event
Market update
Published
03 Jul 2026 12:40
Source
Ad-hoc-news.de
Sahm Direct company coverage

Why Did Curis (CRIS) Stock Soar After Hours?

Curis, Inc. (CRIS) stock surged 8.51% after hours following the confirmation of a reverse stock split. The split, ranging from 1-for-5 to 1-for-25, is intended to help the company regain compliance with Nasdaq's minimum bid price rule. CRIS has a market capitalization of $16.52 m

Tone
Positive 63/100
Event
Market update
Published
03 Jul 2026 00:39
Source
Sahm
Stock Titan Direct company coverage

Curis (NASDAQ: CRIS) sets 1-for-20 reverse split and adjusts equity awards

Curis, Inc. has implemented a 1-for-20 reverse stock split of its common stock, effective July 2, 2026, at 5:00 p.m. Eastern Time. This action consolidates 20 shares into one, with fractional shares rounded up, and will not alter the par value or authorized shares. Trading on a s

Tone
Neutral 50/100
Event
Market update
Published
02 Jul 2026 13:10
Source
Stock Titan